Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 5/20 | 0.65 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.65 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ULK1 | O75385 | 3/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.51 |
| ▸ | CDK7 | P50613 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 4/20 | 0.48 |
| ▸ | JAK2 | O60674 | 3/20 | 0.48 |
| ▸ | JAK1 | P23458 | 3/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.47 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29777593 | 1.00 | MAPK10 (0.65) | MAPK10MAPK8MAPK3MAPK1ULK1 | |
| SCHEMBL12887553 | 0.88 | MAPK10 (0.52) | MAPK10MAPK8MAPK3MAPK1ULK1 | |
| SCHEMBL12413615 | 0.87 | MAPK3 (0.68) | MAPK10MAPK8MAPK3MAPK1ULK1 | |
| SCHEMBL691337 | 0.87 | MAPK10 (0.51) | MAPK10MAPK8MAPK3MAPK1ULK1 | |
| SCHEMBL1232428 | 0.87 | MAPK10 (0.62) | MAPK10MAPK8MAPK3MAPK1ULK1 | |
| SCHEMBL13060634 | 0.87 | MAPK10 (0.51) | MAPK10MAPK8MAPK3MAPK1ULK1 | |
| SCHEMBL1558027 | 0.87 | MAPK10 (0.51) | MAPK10MAPK8MAPK3MAPK1ULK1 | |
| SCHEMBL690498 | 0.86 | PTK2 (0.60) | MAPK10MAPK8MAPK3MAPK1ULK1 | |
| SCHEMBL690156 | 0.86 | MAPK8 (0.50) | MAPK10MAPK8MAPK3MAPK1ULK1 | |
| SCHEMBL29777601 | 0.86 | PTK2 (0.60) | MAPK10MAPK8MAPK3MAPK1ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580439-B2 | Inhibitors of focal adhesion kinase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580439-B2 | Inhibitors of focal adhesion kinase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580439-B2 | Inhibitors of focal adhesion kinase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-02-28 | — | — | US | disclosed |
| US-9446034-B2 | Pyrazolylaminopyridines as inhibitors of FAK | GLAXOSMITHKLINE LLC (US) | 2016-09-20 | — | — | US | disclosed |
| US-9446034-B2 | Pyrazolylaminopyridines as inhibitors of FAK | GLAXOSMITHKLINE LLC (US) | 2016-09-20 | — | — | US | disclosed |
| US-9446034-B2 | Pyrazolylaminopyridines as inhibitors of FAK | GLAXOSMITHKLINE LLC (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160095841-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2016-04-07 | — | — | US | disclosed |
| US-20160095841-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2016-04-07 | — | — | US | disclosed |
| US-20160095841-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2016-04-07 | — | — | US | disclosed |
| US-20150265589-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2015-09-24 | — | — | US | disclosed |
| EP-2303861-A1 | PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2010062578-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010062578-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | disclosed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | disclosed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | disclosed |
| WO-2009153589-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | PTK2, CABLES1, TNK2 | MAPK10 590/4885MAPK8 558/4885MAPK3 185/4885 |
| US-20160095841-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | MAPK10 656/4885MAPK8 912/4885MAPK3 64/4885 |
| US-20150265589-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | MAPK10 656/4885MAPK8 912/4885MAPK3 64/4885 |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | MAPK10 656/4885MAPK8 912/4885MAPK3 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.